FY2024 Earnings Estimate for BIO Issued By Zacks Research

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research increased their FY2024 earnings estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $10.18 per share for the year, up from their previous estimate of $9.46. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.93 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.28 EPS, FY2025 earnings at $11.44 EPS, Q1 2026 earnings at $3.15 EPS and Q2 2026 earnings at $3.08 EPS.

Other equities analysts have also issued research reports about the company. Royal Bank of Canada upped their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 target price on the stock. Citigroup increased their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $391.80.

Bio-Rad Laboratories Trading Up 2.3 %

BIO opened at $332.91 on Monday. The stock has a market capitalization of $9.32 billion, a PE ratio of -12.18 and a beta of 0.93. Bio-Rad Laboratories has a one year low of $262.12 and a one year high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The business’s 50 day moving average price is $340.52 and its 200 day moving average price is $316.27.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.85. The company had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. Bio-Rad Laboratories’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.33 EPS.

Insider Buying and Selling at Bio-Rad Laboratories

In related news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP James Barry sold 623 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. The trade was a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in BIO. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the period. Capital Advisors Ltd. LLC grew its holdings in Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after acquiring an additional 62 shares in the last quarter. Gladius Capital Management LP purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $32,000. EntryPoint Capital LLC acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at $51,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth $55,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.